Healthcare Investment Weekly Report: Zai Lab Lists on HKEX, Johnson & Johnson Acquires Momenta for $6.5 Billion
Johnson & Johnson
Healthcare Product Manufacturers, Health Service Providers
Momenta Pharmaceuticals
Immune Disease Drug Developer
EO Healthcare Weekly Financing Update: Two Companies Go Public; Ten Companies Disclose Financing Deals Globally, Covering Innovative Drugs, AI-Driven Drug R&D, Precision Medicine, and Immune Antibody Therapeutics
Market Launch
On September 28, Zai Lab listed on the Hong Kong Stock Exchange. Zai Lab is an innovative biopharmaceutical company whose primary business model is license-in (in-licensing of patented technologies). In September 2017, Zai Lab successfully listed on the NASDAQ in the United States.
On the same day, Imeik was listed on the ChiNext board of the Shenzhen Stock Exchange. Founded in 2014, Imeik is a company primarily engaged in the independent research and development and sales of products based on sodium hyaluronate. It is the first enterprise in China to obtain medical device registration certificates for related products, with multiple products holding the only Class III medical device certificates in the country.
Focusing on the Patent Licensing-In Model, Zai Lab Lists on Hong Kong Stock Exchange Today
Financing
On September 28, InventisBio (Shanghai) Co., Ltd. (“InventisBio”), a company dedicated to the independent research and development of innovative small-molecule drugs, completed its Series D financing round, with a total fundraising amount of RMB 1 billion.
Yifang Biopharma is a clinical-stage biopharmaceutical company dedicated to developing first-in-class and best-in-class innovative drugs with independent intellectual property rights for the treatment of major diseases such as cancer and metabolic disorders.
On the same day, XtalPi, an AI-driven drug discovery company powered by digitalization and intelligence, announced that it had oversubscribed its $318.8 million Series C financing round, setting a new global record for funding in the AI drug discovery sector.
Broncus, a Leader in Precision Interventional Therapies for Pulmonary Diseases, Announces Completion of Tens of Millions of USD in Series C Financing. The proceeds from this round will be primarily used to consolidate and expand Broncus’s core product portfolio for the diagnosis and treatment of pulmonary diseases, accelerate the R&D, clinical studies, regulatory approvals, and diversified global market deployment of new products, thereby helping Broncus maintain its leading position in the field of precision interventional therapies for pulmonary diseases.
AI Drug Discovery Firm XtalPi Secures $300 Million in Series C Funding, Led by SoftBank Vision Fund
Dedicated to Fluorinated Drug R&D, Aikang Pharma Completes 30 Million Financing
Acquisition
On October 2, Johnson & Johnson announced the successful acquisition of Momenta for $6.5 billion, expanding its footprint in the field of autoimmune diseases. This transaction marks the largest merger and acquisition deal in the U.S. pharmaceutical industry this year. The previous major acquisition occurred in March, when Gilead agreed to acquire the biotechnology company Forty Seven for $4.9 billion.
Momenta is a company developing novel therapies and drugs for autoimmune diseases, with its R&D pipeline focused on Fc-related modalities, including FcRn antibodies, highly sialylated IgG, and Fc polymers. Under the terms of the acquisition, Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, will be able to utilize Nipocalimab, an experimental therapy (an FcRn antibody) developed by Momenta.
Bloomage Biotech Acquires Dongying Fosite Biological Engineering Co., Ltd.
This article is sourced from Yiou, an original piece by author Jasmine. For reprint or collaboration inquiries, please click here.Reprint Notice, Unauthorized reposting will be subject to legal action.